Use of Imaging Endpoints in Clinical Trials
Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is bein...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gillam, Linda D. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Market co-movement between credit default swap curves and option volatility surfaces - Shi, Yukun ELSEVIER, 2022, a journal of the American College of Cardiology, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:10 ; year:2017 ; number:3 ; pages:296-303 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jcmg.2016.12.003 |
|---|
| Katalog-ID: |
ELV020248261 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV020248261 | ||
| 003 | DE-627 | ||
| 005 | 20230625131503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcmg.2016.12.003 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017011000002.pica |
| 035 | |a (DE-627)ELV020248261 | ||
| 035 | |a (ELSEVIER)S1936-878X(16)31016-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 330 |q VZ |
| 084 | |a 83.52 |2 bkl | ||
| 100 | 1 | |a Gillam, Linda D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of Imaging Endpoints in Clinical Trials |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. | ||
| 520 | |a Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. | ||
| 650 | 7 | |a core laboratory |2 Elsevier | |
| 650 | 7 | |a cardiac magnetic resonance imaging |2 Elsevier | |
| 650 | 7 | |a cardiac computed tomography |2 Elsevier | |
| 650 | 7 | |a echocardiography |2 Elsevier | |
| 650 | 7 | |a clinical trials |2 Elsevier | |
| 650 | 7 | |a imaging |2 Elsevier | |
| 650 | 7 | |a nuclear cardiology |2 Elsevier | |
| 700 | 1 | |a Leipsic, Jonathon |4 oth | |
| 700 | 1 | |a Weissman, Neil J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Shi, Yukun ELSEVIER |t Market co-movement between credit default swap curves and option volatility surfaces |d 2022 |d a journal of the American College of Cardiology |g Amsterdam |w (DE-627)ELV008059039 |
| 773 | 1 | 8 | |g volume:10 |g year:2017 |g number:3 |g pages:296-303 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcmg.2016.12.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 83.52 |j Finanzwissenschaft |q VZ |
| 951 | |a AR | ||
| 952 | |d 10 |j 2017 |e 3 |h 296-303 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
l d g ld ldg |
|---|---|
| matchkey_str |
gillamlindadleipsicjonathonweissmanneilj:2017----:soiaignpitici |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
83.52 |
| publishDate |
2017 |
| allfields |
10.1016/j.jcmg.2016.12.003 doi GBVA2017011000002.pica (DE-627)ELV020248261 (ELSEVIER)S1936-878X(16)31016-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ 83.52 bkl Gillam, Linda D. verfasserin aut Use of Imaging Endpoints in Clinical Trials 2017transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Elsevier Leipsic, Jonathon oth Weissman, Neil J. oth Enthalten in Elsevier Shi, Yukun ELSEVIER Market co-movement between credit default swap curves and option volatility surfaces 2022 a journal of the American College of Cardiology Amsterdam (DE-627)ELV008059039 volume:10 year:2017 number:3 pages:296-303 extent:8 https://doi.org/10.1016/j.jcmg.2016.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 83.52 Finanzwissenschaft VZ AR 10 2017 3 296-303 8 045F 610 |
| spelling |
10.1016/j.jcmg.2016.12.003 doi GBVA2017011000002.pica (DE-627)ELV020248261 (ELSEVIER)S1936-878X(16)31016-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ 83.52 bkl Gillam, Linda D. verfasserin aut Use of Imaging Endpoints in Clinical Trials 2017transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Elsevier Leipsic, Jonathon oth Weissman, Neil J. oth Enthalten in Elsevier Shi, Yukun ELSEVIER Market co-movement between credit default swap curves and option volatility surfaces 2022 a journal of the American College of Cardiology Amsterdam (DE-627)ELV008059039 volume:10 year:2017 number:3 pages:296-303 extent:8 https://doi.org/10.1016/j.jcmg.2016.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 83.52 Finanzwissenschaft VZ AR 10 2017 3 296-303 8 045F 610 |
| allfields_unstemmed |
10.1016/j.jcmg.2016.12.003 doi GBVA2017011000002.pica (DE-627)ELV020248261 (ELSEVIER)S1936-878X(16)31016-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ 83.52 bkl Gillam, Linda D. verfasserin aut Use of Imaging Endpoints in Clinical Trials 2017transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Elsevier Leipsic, Jonathon oth Weissman, Neil J. oth Enthalten in Elsevier Shi, Yukun ELSEVIER Market co-movement between credit default swap curves and option volatility surfaces 2022 a journal of the American College of Cardiology Amsterdam (DE-627)ELV008059039 volume:10 year:2017 number:3 pages:296-303 extent:8 https://doi.org/10.1016/j.jcmg.2016.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 83.52 Finanzwissenschaft VZ AR 10 2017 3 296-303 8 045F 610 |
| allfieldsGer |
10.1016/j.jcmg.2016.12.003 doi GBVA2017011000002.pica (DE-627)ELV020248261 (ELSEVIER)S1936-878X(16)31016-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ 83.52 bkl Gillam, Linda D. verfasserin aut Use of Imaging Endpoints in Clinical Trials 2017transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Elsevier Leipsic, Jonathon oth Weissman, Neil J. oth Enthalten in Elsevier Shi, Yukun ELSEVIER Market co-movement between credit default swap curves and option volatility surfaces 2022 a journal of the American College of Cardiology Amsterdam (DE-627)ELV008059039 volume:10 year:2017 number:3 pages:296-303 extent:8 https://doi.org/10.1016/j.jcmg.2016.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 83.52 Finanzwissenschaft VZ AR 10 2017 3 296-303 8 045F 610 |
| allfieldsSound |
10.1016/j.jcmg.2016.12.003 doi GBVA2017011000002.pica (DE-627)ELV020248261 (ELSEVIER)S1936-878X(16)31016-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ 83.52 bkl Gillam, Linda D. verfasserin aut Use of Imaging Endpoints in Clinical Trials 2017transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Elsevier Leipsic, Jonathon oth Weissman, Neil J. oth Enthalten in Elsevier Shi, Yukun ELSEVIER Market co-movement between credit default swap curves and option volatility surfaces 2022 a journal of the American College of Cardiology Amsterdam (DE-627)ELV008059039 volume:10 year:2017 number:3 pages:296-303 extent:8 https://doi.org/10.1016/j.jcmg.2016.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 83.52 Finanzwissenschaft VZ AR 10 2017 3 296-303 8 045F 610 |
| language |
English |
| source |
Enthalten in Market co-movement between credit default swap curves and option volatility surfaces Amsterdam volume:10 year:2017 number:3 pages:296-303 extent:8 |
| sourceStr |
Enthalten in Market co-movement between credit default swap curves and option volatility surfaces Amsterdam volume:10 year:2017 number:3 pages:296-303 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Finanzwissenschaft |
| institution |
findex.gbv.de |
| topic_facet |
core laboratory cardiac magnetic resonance imaging cardiac computed tomography echocardiography clinical trials imaging nuclear cardiology |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Market co-movement between credit default swap curves and option volatility surfaces |
| authorswithroles_txt_mv |
Gillam, Linda D. @@aut@@ Leipsic, Jonathon @@oth@@ Weissman, Neil J. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008059039 |
| dewey-sort |
3610 |
| id |
ELV020248261 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV020248261</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625131503.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcmg.2016.12.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017011000002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV020248261</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1936-878X(16)31016-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">83.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gillam, Linda D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of Imaging Endpoints in Clinical Trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">core laboratory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cardiac magnetic resonance imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cardiac computed tomography</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">echocardiography</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">clinical trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">nuclear cardiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leipsic, Jonathon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weissman, Neil J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Shi, Yukun ELSEVIER</subfield><subfield code="t">Market co-movement between credit default swap curves and option volatility surfaces</subfield><subfield code="d">2022</subfield><subfield code="d">a journal of the American College of Cardiology</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV008059039</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:296-303</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcmg.2016.12.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">83.52</subfield><subfield code="j">Finanzwissenschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2017</subfield><subfield code="e">3</subfield><subfield code="h">296-303</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Gillam, Linda D. |
| spellingShingle |
Gillam, Linda D. ddc 610 ddc 330 bkl 83.52 Elsevier core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Use of Imaging Endpoints in Clinical Trials |
| authorStr |
Gillam, Linda D. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008059039 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 330 - Economics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 330 VZ 83.52 bkl Use of Imaging Endpoints in Clinical Trials core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology Elsevier |
| topic |
ddc 610 ddc 330 bkl 83.52 Elsevier core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology |
| topic_unstemmed |
ddc 610 ddc 330 bkl 83.52 Elsevier core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology |
| topic_browse |
ddc 610 ddc 330 bkl 83.52 Elsevier core laboratory Elsevier cardiac magnetic resonance imaging Elsevier cardiac computed tomography Elsevier echocardiography Elsevier clinical trials Elsevier imaging Elsevier nuclear cardiology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j l jl n j w nj njw |
| hierarchy_parent_title |
Market co-movement between credit default swap curves and option volatility surfaces |
| hierarchy_parent_id |
ELV008059039 |
| dewey-tens |
610 - Medicine & health 330 - Economics |
| hierarchy_top_title |
Market co-movement between credit default swap curves and option volatility surfaces |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008059039 |
| title |
Use of Imaging Endpoints in Clinical Trials |
| ctrlnum |
(DE-627)ELV020248261 (ELSEVIER)S1936-878X(16)31016-6 |
| title_full |
Use of Imaging Endpoints in Clinical Trials |
| author_sort |
Gillam, Linda D. |
| journal |
Market co-movement between credit default swap curves and option volatility surfaces |
| journalStr |
Market co-movement between credit default swap curves and option volatility surfaces |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
296 |
| author_browse |
Gillam, Linda D. |
| container_volume |
10 |
| physical |
8 |
| class |
610 610 DE-600 330 VZ 83.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gillam, Linda D. |
| doi_str_mv |
10.1016/j.jcmg.2016.12.003 |
| dewey-full |
610 330 |
| title_sort |
use of imaging endpoints in clinical trials |
| title_auth |
Use of Imaging Endpoints in Clinical Trials |
| abstract |
Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. |
| abstractGer |
Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. |
| abstract_unstemmed |
Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
3 |
| title_short |
Use of Imaging Endpoints in Clinical Trials |
| url |
https://doi.org/10.1016/j.jcmg.2016.12.003 |
| remote_bool |
true |
| author2 |
Leipsic, Jonathon Weissman, Neil J. |
| author2Str |
Leipsic, Jonathon Weissman, Neil J. |
| ppnlink |
ELV008059039 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.jcmg.2016.12.003 |
| up_date |
2024-07-06T17:05:58.656Z |
| _version_ |
1803850149956419584 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV020248261</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625131503.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcmg.2016.12.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017011000002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV020248261</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1936-878X(16)31016-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">83.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gillam, Linda D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of Imaging Endpoints in Clinical Trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cardiovascular imaging is an integral component of many clinical trials beyond those for which the primary goal is to evaluate or validate imaging technologies. The scope of such trials is broad, ranging from those in which a medical, surgical, or interventional cardiovascular device or drug is being evaluated to those in which there is concern about cardiovascular adverse events complicating treatment for noncardiac conditions. This paper discusses study design as it pertains to the incorporation of imaging elements, the important role played by imaging core laboratories, the rationale for and approaches to involvement of imagers in clinical trials, and guidance by the U.S. Food and Drug Administration on imaging endpoints in clinical trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">core laboratory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cardiac magnetic resonance imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cardiac computed tomography</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">echocardiography</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">clinical trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">nuclear cardiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leipsic, Jonathon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weissman, Neil J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Shi, Yukun ELSEVIER</subfield><subfield code="t">Market co-movement between credit default swap curves and option volatility surfaces</subfield><subfield code="d">2022</subfield><subfield code="d">a journal of the American College of Cardiology</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV008059039</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:296-303</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcmg.2016.12.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">83.52</subfield><subfield code="j">Finanzwissenschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2017</subfield><subfield code="e">3</subfield><subfield code="h">296-303</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4018593 |